2400 related articles for article (PubMed ID: 7541995)
1. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
[TBL] [Abstract][Full Text] [Related]
2. Antiallergic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidaz ole difumarate (KB-2413).
Fukuda T; Saito T; Tajima S; Shimohara K; Ito K
Arzneimittelforschung; 1984; 34(7):805-10. PubMed ID: 6208915
[TBL] [Abstract][Full Text] [Related]
3. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent.
Benavides J; Schoemaker H; Dana C; Claustre Y; Delahaye M; Prouteau M; Manoury P; Allen J; Scatton B; Langer SZ
Arzneimittelforschung; 1995 May; 45(5):551-8. PubMed ID: 7612054
[TBL] [Abstract][Full Text] [Related]
5. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat.
Pichat P; Angel I; Arbilla S
Arzneimittelforschung; 1998 Feb; 48(2):173-8. PubMed ID: 9541729
[TBL] [Abstract][Full Text] [Related]
7. Effects of E-4716, a new antihistaminic with antiallergic properties, on chemical mediators induction of immunologic reactions.
Gutiérrez B; Dordal A; Fort M; Galicia J; Farré AJ
Methods Find Exp Clin Pharmacol; 1996; 18(6):397-406. PubMed ID: 8892269
[TBL] [Abstract][Full Text] [Related]
8. Anti-allergic effects of ketanserin on animal models of allergic reactions.
Nagai H; Suda H; Kitagaki K; Goto S; Miura T; Koda A
Arch Int Pharmacodyn Ther; 1990; 307():172-82. PubMed ID: 1710442
[TBL] [Abstract][Full Text] [Related]
9. Antiallergic profile of the novel H1-antihistaminic compound levocabastine.
Tasaka K; Kamei C; Akagi M; Mio M; Shirasaka T; Chokki M
Arzneimittelforschung; 1993 Dec; 43(12):1331-7. PubMed ID: 7511378
[TBL] [Abstract][Full Text] [Related]
10. Antiallergic effects of astemizole on immediate type hypersensitivity reactions.
Tasaka K; Akagi M; Izushi K; Mio M
Methods Find Exp Clin Pharmacol; 1990 Oct; 12(8):531-9. PubMed ID: 1709434
[TBL] [Abstract][Full Text] [Related]
11. Antiallergic activity and mode of action of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3- pyridyl)acrylamide in experimental animals.
Ishii K; Yakuo I; Seto Y; Kita A; Nakamura H; Nishikawa Y
Arzneimittelforschung; 1993 Feb; 43(2):148-54. PubMed ID: 7681286
[TBL] [Abstract][Full Text] [Related]
12. Effects of 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3- (1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid with thromboxane A2 synthetase inhibitory and H1-blocking activities on anaphylactic bronchospasm.
Nakamura S; Shirahase H; Kanda M; Wada K; Kamiya S; Matsui H; Kurahashi K
Arzneimittelforschung; 1996 Nov; 46(11):1067-71. PubMed ID: 8955866
[TBL] [Abstract][Full Text] [Related]
13. Effect of loratadine on immediate and delayed type hypersensitivity reactions.
Tasaka K; Kamei C; Akagi M; Mio M; Izushi K; Yoshida T; Nakamura S
Arzneimittelforschung; 1995 Jul; 45(7):796-804. PubMed ID: 8573225
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
15. Effect of SA-103 on experimental allergic models in vivo and in vitro--comparison with disodium cromoglycate.
Nabe T; Yamamura H; Kohno S; Ohata K
Arerugi; 1992 Jun; 41(6):676-85. PubMed ID: 1280084
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
Hwang SB; Li CL; Lam MH; Shen TY
Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
[TBL] [Abstract][Full Text] [Related]
17. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
18. Antianaphylactic and antihistaminic activity of the non-steroidal anti-inflammatory compound nimesulide in guinea-pig.
Berti F; Rossoni G; Buschi A; Robuschi M; Villa LM
Arzneimittelforschung; 1990 Sep; 40(9):1011-6. PubMed ID: 1981969
[TBL] [Abstract][Full Text] [Related]
19. Anti-allergic properties of ethyl-3-methoxyphenyl-4-thiazolyl-2-oxamate (F 1865).
Tarayre JP; Lauressergues H; Fauran F
Arch Int Pharmacodyn Ther; 1982 Nov; 260(1):165-76. PubMed ID: 6187305
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
